Genflow Biosciences PLC Announces Result of AGM
Rhea-AI Summary
Genflow Biosciences (OTCQB:GENFF) reported that all 13 resolutions at its 29 June 2026 AGM were passed. Ordinary business included receiving 2025 accounts, approving the remuneration report, reappointing PKF Littlejohn as auditor and re-electing all directors.
Shareholders also approved a new share option scheme, authorising directors to allot shares for scheme options up to 14.34% and to allot further shares up to 33%. Special resolutions to disapply statutory pre-emption rights related to these allotment authorities were passed with over 98.7% support.
Positive
- All 13 AGM resolutions passed, supporting governance and strategic flexibility
- Reappointment of PKF Littlejohn as auditor received 99.94% of votes cast
- All directors re-elected with at least 99.70% of votes cast in favour
- Share option scheme approved with 98.86% of votes cast in favour
- Authority to allot shares up to 33% approved with 98.86% support
- Pre-emption disapplication resolutions passed with at least 98.79% support
Negative
- Share option scheme and related allotment authority enable potential dilution up to 14.34%
- General share allotment authority enables potential dilution up to 33% of share capital
- Pre-emption rights disapplied for new issues under these authorities, reducing default shareholder protections
- Resolutions on share options and pre-emption saw the highest opposition, up to 1.21% of votes cast
AI-generated analysis. How Rhea-AI works. Not financial advice.
LONDON, UK / ACCESS Newswire / June 29, 2026 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company") an emerging leader in the field of longevity research, is pleased to announce that all resolutions proposed at the Annual General Meeting held earlier today were duly passed by shareholders. The number of proxy votes for each resolution submitted prior to the meeting are presented below.
Proxy Voting Results
Ordinary Resolutions | Votes for | % of votes cast for | Votes Against | % of votes cast against | Total votes cast | Votes withheld |
1. To receive and consider the Annual Report and Accounts for the year ended 31 December 2025 together with the Directors' Report and Auditors' Report thereon. | 102,370,028 | 56,893 | 102,426,921 | 1,058 | ||
2. To approve the directors' remuneration report for the financial period ended 31 December 2025 set out in the audited accounts for the financial period ended 31 December 2025. | 102,348,305 | 78,616 | 102,426,921 | 1,058 | ||
3. To re-appoint PKF Littlejohn LLP as auditors of the Company and to authorise the Directors of the Company to fix their remuneration. | 102,370,094 | 56,603 | 102,426,697 | 1,282 | ||
4. To re-elect Gad Berdugo as a Director of the Company. | 102,363,749 | 64,006 | 102,427,755 | 224 | ||
5. To re-elect Dr Eric Leire as a Director of the Company. | 102,363,557 | 64,198 | 102,427,755 | 224 | ||
6. To re-elect Tamara Joseph as a Director of the Company. | 102,363,557 | 64,198 | 102,427,755 | 224 | ||
7. To re-elect Dr Yassine Bendiabdallah as a Director of the Company. | 102,363,459 | 64,296 | 102,427,755 | 224 | ||
8. To re-elect Guy-Charles Fanneau De La Horie as a Director of the Company. | 102,363,459 | 64,296 | 102,427,755 | 224 | ||
9. To approve the adoption of the share option scheme (the "Scheme") by the Company. | 101,237,554 | 1,162,031 | 102,399,585 | 28,394 | ||
10. To authorise the Directors of the Company to allot shares for the Scheme Options (up to | 101,264,434 | 1,162,321 | 102,426,465 | 1,224 | ||
11. To authorise the Directors of the Company to allot shares (up to | 101,264,724 | 1,162,031 | 102,426,755 | 1,224 | ||
Special Resolution | Votes for | % of votes cast for | Votes Against | % of votes cast against | Total votes cast | Votes withheld |
12. To disapply statutory pre-emption rights in respect of Resolution 10 (Scheme Options) | 101,218,852 | 1,208,127 | 102,426,979 | 1,000 | ||
13. To disapply statutory pre-emption rights in respect of Resolution 11 | 101,191,458 | 1,235,521 | 102,426,979 | 1,000 |
Contacts | |
Genflow Biosciences | Harbor Access |
Dr Eric Leire, CEO | Jonathan Paterson, Investor Relations |
+32-477-495-881 | +1 475 477 9401 |
|
About Genflow
Founded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies for age-related diseases, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Genflow's proof-of-concept clinical trial evaluating its SIRT6-centenarian gene therapy in aged dogs began in March 2025. Other programs include a clinical trial that will explore the potential benefits of GF-1002 in treating MASH (Metabolic Dysfunction Associated Steatohepatitis), the most prevalent chronic liver disease for which there is no effective treatments.
Please visit www.genflowbio.com and follow the Company on LinkedIn and Twitter/X.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: Genflow Biosciences PLC
View the original press release on ACCESS Newswire